土耳其称中国科兴的Sinovac COVID疫苗在后期试验中有效率为91.25％
来源：https://www.reuters.com/article/us-health-coronavirus-turkey-china/turkey-says-chinas-sinovac-covid-vaccine-91-25-effective-in-late-trials-idUSKBN28Y1R1
google译文（tldr）：
根据土耳其的后期试验的中期数据，由中国Sinovac生物技术公司开发的COVID-19疫苗有效率为91.25％，其结果可能比在巴西进行的单独试验所报告的结果要好得多。
上个月辉瑞（Pfizer），摩德纳（Moderna）和阿斯利康（AstraZeneca）的竞争对手产品取得了积极成果，科兴生物（Sinovac）是第一家公布后期临床试验细节的中国疫苗生产商。
科卡说：“我们现在确定这种疫苗对土耳其人是有效和安全的。”他补充说，安卡拉将使用这些数据来获得该疫苗的许可。
此前，巴西的试验结果说有效率超过50%，但是把试验结果的公布从原定的12月23日推迟15天，因为当时土耳其和印尼的结果还没有出来。
https://www.wsj.com/articles/chinas-sinovac-delays-covid-19-vaccine-trial-results-11608757865
google译文（tldr）：
根据土耳其的后期试验的中期数据，由中国Sinovac生物技术公司开发的COVID-19疫苗有效率为91.25％，其结果可能比在巴西进行的单独试验所报告的结果要好得多。
上个月辉瑞（Pfizer），摩德纳（Moderna）和阿斯利康（AstraZeneca）的竞争对手产品取得了积极成果，科兴生物（Sinovac）是第一家公布后期临床试验细节的中国疫苗生产商。
科卡说：“我们现在确定这种疫苗对土耳其人是有效和安全的。”他补充说，安卡拉将使用这些数据来获得该疫苗的许可。
此前，巴西的试验结果说有效率超过50%，但是把试验结果的公布从原定的12月23日推迟15天，因为当时土耳其和印尼的结果还没有出来。
https://www.wsj.com/articles/chinas-sinovac-delays-covid-19-vaccine-trial-results-11608757865
48 个评论
试验数据会因为不同种族而不同。Pfizer疫苗对非洲裔100%有效，对拉丁裔94.5%有效，对亚裔74.4%有效。
https://www.latimes.com/science/story/2020-12-15/how-the-covid-19-vaccines-from-moderna-and-pfizer-compare-head-to-head
Did the vaccines help people of color?
All five of the people in the Moderna trial who developed COVID-19 after receiving the vaccine were white. As a result, the Moderna vaccine was 100% effective in Black, Latino and Asian Americans, as well as in people with mixed racial backgrounds. Vaccine efficacy could not be determined for Native Americans or Pacific Islanders because there were no cases of COVID-19 in either the vaccine or the placebo groups.
In its Phase 3 trial, the Pfizer vaccine was 100% effective for Black study participants and 94.5% effective for Latino participants, slightly below the 94.7% effectiveness for white subjects. In addition, it was 74.4% effective in Asian Americans, and 100% effective in Native Americans and Pacific Islanders. Among people described as multiracial, it was only 10.4% effective, with one case of COVID-19 among those who got the vaccine and one case among those who got the placebo.
https://www.latimes.com/science/story/2020-12-15/how-the-covid-19-vaccines-from-moderna-and-pfizer-compare-head-to-head
All five of the people in the Moderna trial who developed COVID-19 after receiving the vaccine were white. As a result, the Moderna vaccine was 100% effective in Black, Latino and Asian Americans, as well as in people with mixed racial backgrounds. Vaccine efficacy could not be determined for Native Americans or Pacific Islanders because there were no cases of COVID-19 in either the vaccine or the placebo groups.
In its Phase 3 trial, the Pfizer vaccine was 100% effective for Black study participants and 94.5% effective for Latino participants, slightly below the 94.7% effectiveness for white subjects. In addition, it was 74.4% effective in Asian Americans, and 100% effective in Native Americans and Pacific Islanders. Among people described as multiracial, it was only 10.4% effective, with one case of COVID-19 among those who got the vaccine and one case among those who got the placebo.